These studies suggest that exogenous EGF and insulin could reduce the sensitivity of EGFR mutant and ALK-translocated NSCLC cells to EGFR or ALK inhibitors, respectively, and should be removed from the media prior to drug sensitivity assays. This evidence concerns the gene EGF and non-small cell lung carcinoma.